KR0149810B1 - Anti-inflammatory agent containing streptomyces s.p mt2705-4 as activating component - Google Patents

Anti-inflammatory agent containing streptomyces s.p mt2705-4 as activating component

Info

Publication number
KR0149810B1
KR0149810B1 KR1019950011228A KR19950011228A KR0149810B1 KR 0149810 B1 KR0149810 B1 KR 0149810B1 KR 1019950011228 A KR1019950011228 A KR 1019950011228A KR 19950011228 A KR19950011228 A KR 19950011228A KR 0149810 B1 KR0149810 B1 KR 0149810B1
Authority
KR
South Korea
Prior art keywords
inflammatory
inflammatory agent
actinomycetes
present
agent containing
Prior art date
Application number
KR1019950011228A
Other languages
Korean (ko)
Other versions
KR960040362A (en
Inventor
안종석
이현선
민태익
박찬선
안순철
김보연
김현표
강대욱
오원근
박병근
Original Assignee
김은영
한국과학기술연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김은영, 한국과학기술연구원 filed Critical 김은영
Priority to KR1019950011228A priority Critical patent/KR0149810B1/en
Publication of KR960040362A publication Critical patent/KR960040362A/en
Application granted granted Critical
Publication of KR0149810B1 publication Critical patent/KR0149810B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 방선균주로부터 분리된 다이아네마이신을 유효성분으로 함유하는 항염증작용제에 관한 것으로서, 더욱 상세하게는 항염활성을 갖는 방선균주를 선정한 다음 통상의 방법으로 분리·정제한 다이아네마이신을 유효성분으로 함유하여 인체의 피부염증치료에 매우 유용한 항염증작용제에 관한 것이다.The present invention relates to an anti-inflammatory agent containing a dianamycin isolated from actinomycetes as an active ingredient, and more particularly, selecting a actinomycete having anti-inflammatory activity and then separating and purifying the thyminesine by a conventional method. The present invention relates to an anti-inflammatory agent which is contained as an ingredient and is very useful for treating skin inflammation of the human body.

Description

방선균주로부터 분리된 다이아네마이신을 유효성분으로 함유하는 항염증작용제Anti-inflammatory agent containing Dianemycin isolated from actinomycetes as an active ingredient

본 발명은 방선균주로부터 분리된 다이아네마이신을 유효성분으로 함유하는 항염증작용제에 관한 것으로서, 더욱 상세하게는 항염활성을 갖는 방선균주를 선정한 다음 통상의 방법으로 분리·정제한 다이아네마이신을 유효성분으로 함유하여 인체의 피부염증치료에 매우 유용한 항염증작용제에 관한 것이다.The present invention relates to an anti-inflammatory agent containing a dianamycin isolated from actinomycetes as an active ingredient, and more particularly, selecting a actinomycete having anti-inflammatory activity and then separating and purifying the thyminesine by a conventional method. The present invention relates to an anti-inflammatory agent which is contained as an ingredient and is very useful for treating skin inflammation of the human body.

염증은 조직이나 세포의 손상으로 인해 백혈구가 이동하거나 통증, 열, 홍반(redness), 종기(swelling), 세포합류(cell influx) 등을 포함하는 복합적인 반응을 보인다. 이러한 반응들은 세포내 인지질을 구성하고 있는 지방산인 아라키돈산으로 부터 생합성되는 프로스타글라딘(prostagladin), 트롬보산(thromboxane), 로이코트리엔(leukotriene), 프로스타시클린(prostacyclin) 등과 같은 화학중재자(chemical mediator)의 작용, 염증부위에 축척된 백혈구로부터 리소조멀(lysosomal) 효소와 반응성 산소의 방출 및 세포내 인지질의 일종으로 프로스타노이드(prostanoid)와 로이코트리엔의 생합성과 관련이 있는 혈소판 활성화 인자(PAF;Platlet-activating factor) 등에 의해 염증세포들이 활성화되어 유도된다.Inflammation is a complex response that involves the movement of white blood cells due to damage to tissues or cells, including pain, fever, redness, swelling, and cell influx. These reactions include chemical mediators such as prostagladin, thromboxane, leukotriene, and prostacyclin, which are biosynthesized from the fatty acid arachidonic acid that makes up phospholipids. The action of chemical mediators, the release of lysosomal enzymes and reactive oxygen from leukocytes accumulated in inflammatory sites, and the activation of platelets associated with the biosynthesis of prostanoids and leukotrienes as a type of intracellular phospholipids. Inflammatory cells are activated and induced by a factor (PAF; Platlet-activating factor).

이와같은 여러가지 작용이나 효소 등을 불활성화시키는 방법으로 항염효과를 나타내는 항염제를 개발하기 위하여 천연물로부터의 분리나 화학합성에 의한 시도가 진행되고 있다.In order to develop an anti-inflammatory agent having an anti-inflammatory effect by a method of inactivating such various actions or enzymes, attempts have been made by separation from natural products and chemical synthesis.

지금까지 개발된 항염제는 스테로이드성화합물로는 덱사메타손(dexamethasone)과 프레드니솔론(prednisolone) 등이 있으며, 비스테로이드성화합물로는 아스피린, 인도메타신(indomethacin) 등이 있다.The anti-inflammatory drugs developed so far include dexamethasone and prednisolone as steroidal compounds, and aspirin and indomethacin as nonsteroidal compounds.

스테로이드성 화합물은 세포내 인지질로부터 아리키돈산(arachidonic acid)을 유리시키는 포스포리파제 A2(phospholipase A2)의 활성을 저해시키고, 비스테로이드성 화합물은 유리된 아라키돈산으로부터 화학중재자에 이르는 생화합 과정에 관여하는 사이클로옥시게나제(cyclooxygenase), 리폭시게나제(lipoxygenase) 등의 효소작용을 저해시킴으로써 항염활성을 나타낸다.Steroidal compounds phospholipase A 2 (phospholipase A 2) the activity and inhibition, the non-steroidal compound is life unity process from a chemical mediator from the free arachidonic acid which releases ahriki donsan (arachidonic acid) from cellular phospholipid It exhibits anti-inflammatory activity by inhibiting enzymatic actions of cyclooxygenase, lipoxygenase, and the like.

그러나, 이러한 스테로이드성 화합물을 장기간 피부에 바를 경우 피부 위축 현상, 쿠싱증후군(cushing's syndrom) 및 어린이의 성장장애를 일으키는 등과 같은 문제가 있으며, 비스테로이드성 화합물은 원래 항염 제제로 개발된 것이 아니라 해열, 진통제로 개발되었기 때문에 스테로이드성 화합물에 비해 항염활성이 낮다.However, long-term application of such steroid compounds to skin causes problems such as skin atrophy, cushing's syndrom, and growth disorders in children.Non-steroidal compounds are not originally developed as anti-inflammatory agents but are antipyretic, Because it was developed as an analgesic agent, its anti-inflammatory activity is lower than that of steroidal compounds.

한편, 다이아네마이신은 방선균주로부터 분리된 물질로서 이미 일본특허공고 소57-58687호에 그 분리방법이 개시된 바 있으며, 지금까지 이 다이아네마이신은 미생물 성장억제등 국부적인 용도로 사료첨가제 등에 이용되어 왔고, 항염증작용제로는 전혀 사용된 바 없다.On the other hand, dianamine is a substance isolated from actinomycetes and the separation method has already been disclosed in Japanese Patent Publication No. 57-58687. Until now, this dainaecin is used as a feed additive for local use such as microbial growth inhibition. It has never been used as an anti-inflammatory agent.

따라서, 본 발명자들은 상기 기존 항염제들의 문제점을 해결하고 보다 개선된 항염제를 개발하고자 노력한 결과, 토양으로부터 방선균주를 분리하고 통상의 방법으로 다이아네마이신을 분리하였으며, 이 물질을 크로톤 오일과 아라키돈산에 의해 유도되는 염증에 대한 저해성을 살펴본 결과 다이아네마이신이 우수한 항염활성을 가짐을 밝힘으로써 본 발명을 완성하였다.Therefore, the present inventors have attempted to solve the problems of the existing anti-inflammatory agents and to develop more improved anti-inflammatory agents, as a result of separating the actinomycetes from the soil and separating the dianomycin in a conventional manner, and the material to croton oil and arachidonic acid As a result of examining the inhibitory effect on the inflammation induced by the present invention, the present invention has been completed by revealing that the thymine has excellent anti-inflammatory activity.

본 발명은 방선균주로부터 분리된 다이아네마이신을 유효성분으로 함유하는 항염제를 제공하는데 그 목적이 있다.It is an object of the present invention to provide an anti-inflammatory agent containing dianemycin isolated from actinomycetes as an active ingredient.

이하, 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.

본 발명은 방선균으로부터 분리된 다이아네마이신을 유효성분으로 함유하는 항염증작용제에 관한 것이다.The present invention relates to an anti-inflammatory agent containing dianemycin isolated from actinomycetes as an active ingredient.

이와같은 본 발명을 더욱 상세히 설명하면 다음과 같다.Referring to the present invention in more detail as follows.

본 발명은 다이아네마이신을 유효성분으로 함유하는 항염증작용제에 관한 것으로서, 본 발명의 방선균주로부터 다이아네마이신을 분리 정제하는 방법에 있어서, 먼저 전국의 토양으로부터 분리된 방선균 중에서 항염활성물질을 생산하는 방선균을 선정하여, 스트렙토마이세스속(Streptomyces sp.) MT 2705-4라 명명하고 1995년 3월 13일자로 한국과학기술연구원 부설 생명공학연구소 유전자은행에 기탁번호 KCTC 8651P로 기탁하였다.The present invention relates to an anti-inflammatory agent containing dianemycin as an active ingredient, and in the method for separating and purifying dianemycin from the actinomycetes of the present invention, first, an anti-inflammatory active material is produced from actinomycetes isolated from soils of the whole country. Actinomycetes were named Streptomyces sp. MT 2705-4 and deposited on March 13, 1995, with the accession number KCTC 8651P to the Gene Bank of Korea Institute of Science and Technology.

본 발명에서 상기 방선균의 생산배지조성물은 물 1ℓ당 수용성 전분 20g, 포도당 10g, 대부분 25g, 효모추출액 4g, 소금 2g 및 제2인산칼륨 0.05g인 것을 기본배지로 한다.The production medium composition of the actinomycetes in the present invention is 20g of water-soluble starch per liter of water, 10g of glucose, mostly 25g, 4g of yeast extract, 2g of salt and 0.05g of dibasic potassium phosphate.

이와같은 조성의 배지를 pH6.5~7.5로 조절하고 멸균하여 선정된 방선균을 접종 후 28℃에서 5일간 진탕 배양한다.The medium of this composition is adjusted to pH 6.5 ~ 7.5 and sterilized by inoculation of the selected actinomycetes, followed by incubation at 28 ° C for 5 days.

배양액을 회수하고 원심분리하여 상등액을 특정수지에 흡착시켜 아세톤으로 활성물질을 용출하고 균체는 60% 아세톤으로 추출하여 상등액의 활성물질과 합해 에틸아세테이트로 추출하였으며 2회에 걸친 컬럼 크로마토그래피법으로 항염활성물질을 분리·정제하였다.The culture was recovered and centrifuged to adsorb the supernatant to a specific resin to elute the active material with acetone. The cells were extracted with 60% acetone, combined with the active material of the supernatant and extracted with ethyl acetate. The active substance was isolated and purified.

이와같이 분리된 항염활성물질을 항균스펙트럼, UV 스펙트럼 및 NMR 스펙트럼 등으로 분석한 결과는 다음과 같으며 사료첨가제로 알려진 폴리에테르 계열의 다이아네마이신(dianemycin)과 동일한 것으로 밝혀졌다.As a result of analyzing the separated anti-inflammatory substances by antibacterial spectrum, UV spectrum and NMR spectrum, the following results were found to be the same as polyether-based dianemycin known as feed additive.

이와같은 방법으로 분리된 다이아네마이신을 웅성의 ICR계 쥐(18~22g)의 귀에 바르고 30분 후, 염증을 유발하기 위하여 2.5% 크로톤 오일 또는 2% 아라키돈산을 동일 부위에 발라 크로톤 오일의 경우 5시간 후, 아리키돈산의 경우는 1시간 후 귀의 두께를 김 등의 방법에 따라 다이알 두께 게이지(dial thickness gauge)로 측정하여 다이아네마이신을 처리하지 않고 발염제만 처리한 대조군과의 항염활성을 비교하였다(Kim et. al., Arch. Pharm. Res. 16(1), 18-24, 1993).30 minutes after applying diaminein isolated in this way to the male ICR rat (18-22g), apply 2.5% croton oil or 2% arachidonic acid to the same site to induce inflammation. After 5 hours, in the case of Arikidonic acid, the thickness of the ear was measured by a dial thickness gauge according to the method such as laver and the like, and the anti-inflammatory activity was compared with the control group treated only with the propellant without the treatment of dianamine. Kim et. Al., Arch. Pharm. Res. 16 (1), 18-24, 1993).

그 결과 다이아네마이신은 그 자체로도 우수한 항염활성을 가짐을 밝혔으며, 나아가서 그람 양성균 및 그람 음성균에 항균활성을 가짐으로써 피부적용 항염제로의 사용 가능성이 높음을 알 수 있다.As a result, it was found that dianamine has excellent anti-inflammatory activity in itself, and furthermore, it has a high antibacterial activity against gram-positive bacteria and gram-negative bacteria, indicating that it can be used as an anti-inflammatory agent for skin application.

이하, 본 발명을 실시예에 의거하여 상세히 설명하면 다음과 같은 바, 본 발명이 실시예에 의해 한정되는 것이 아니다.Hereinafter, the present invention will be described in detail with reference to the following Examples, the present invention is not limited by the Examples.

[실시예 1]Example 1

방선균의 생산Production of actinomycetes

물 1ℓ당 수용성 전분 20g, 포도아 10g, 대두분 25g, 효모추출액 4g, 소금 2g 및 제2인산칼륨 0.05g을 가하고 pH 7.3으로 조절한 다음, 멸균한 뒤 선정된 스트렙토마이세스 MT 2705-4(KCTC 8651P) 균주를 접종하고 28℃에서 5일간 진탕 배양하였다.20 g of water-soluble starch, 10 g of grape seed, 25 g of soybean meal, 4 g of yeast extract, 2 g of salt and 0.05 g of potassium diphosphate were added thereto, adjusted to pH 7.3, sterilized and selected Streptomyces MT 2705-4 ( KCTC 8651P) strains were inoculated and shaken at 28 ° C. for 5 days.

[실시예 2]Example 2

항염활성물질의 분리Isolation of Anti-inflammatory Active Material

상기 실시예 1로부터 얻은 방선균 배양액을 회수하여 600rpm으로 원심분리한 후 상등액을 다이아이온(Diaion) HP-20(미쓰비시사 제품)에 흡착시켜 50% 아세톤으로 활성물질을 용출하고, 남은 균체는 60% 아세톤으로 추출하여 상등액 용출액과 합하였다.The actinomycetes culture medium obtained in Example 1 was recovered and centrifuged at 600 rpm, and then the supernatant was adsorbed onto Diaion HP-20 (manufactured by Mitsubishi Corporation) to elute the active material with 50% acetone, and the remaining cells were 60%. Extracted with acetone and combined with the supernatant eluate.

합한 용액을 에틸아세테이트로 용매추출하여 활성분획을 얻고 클로로포롬:메탄올(100:1)의 혼합액을 전개용매로 실리카겔 컬럼 크로마토그래피하여 활성분획을 모았다. 분리된 활성분획을 세파덱스(Sephadex) LH-20(시그마사 제품) 컬럼에 흡착시켜 클로로포롬:메탄올(1:1)의 혼합액으로 용출하여 다이아네마이신을 순수 분리하였다.The combined solution was solvent-extracted with ethyl acetate to obtain an active fraction, and the active fractions were collected by silica gel column chromatography using a mixture of chloroform: methanol (100: 1) as a developing solvent. The separated active fraction was adsorbed onto a Sephadex LH-20 (manufactured by Sigma Co., Ltd.) column, eluted with a mixed solution of chloroform: methanol (1: 1), and dianemycin was purified purely.

[실험예 1]Experimental Example 1

스테로이드 화합물의 경우 크로톤 오일에 의해 유도되는 염증에 대해 저해활성이 높으므로 본 발명의 다이아네마이신과 시판되고 있는 스테로이드 화합물 항염 제제인 프레드니솔론과 항염활성을 비교하기 위하여 각각을 적당량의 아세톤에 녹여 웅성의 ICR계 쥐(18~22g)의 귀에 바르고 30분이 경과한 뒤 2.5% 크로톤 오일을 동일한 부위에 발라 귀의 염증을 유도하였다. 5시간 후, 귀의 두께를 다이알 두께 게이지로 측정하여 시료를 처리하지 않은 쥐 귀의 두께와 비교하여 염증을 저해하는 정도를 비교하였으며, 그 결과는 다음 표 1에 나타낸 바와같다.Since steroid compounds have high inhibitory activity against inflammation induced by croton oil, each of the steroid compounds is dissolved in an appropriate amount of acetone in order to compare the anti-inflammatory activity of dianimecin of the present invention with prednisolone, a commercial anti-inflammatory agent of steroid compounds. After 30 minutes of application to the ears of ICR rats (18-22 g), 2.5% croton oil was applied to the same site to induce inflammation of the ears. After 5 hours, the thickness of the ear was measured with a dial thickness gauge to compare the degree of inflammation inhibition compared with the thickness of the untreated rat ear, and the results are shown in Table 1 below.

[실험예 2]Experimental Example 2

비스테로이드 화합물과 시클로옥시게나제 저해물질의 경우 아라키돈산에 의해 유도되는 염증에 대한 저해활성이 높으므로 분리된 다이아네마이신과 비스테로이드 화합물인 인도메타신과의 항염활성을 비교하기 위하여 각각을 적당량의 아세톤에 녹여 웅성의 ICR계 쥐(18~22g)의 귀에 바르고 30분이 경과한 뒤 2% 아라키돈산을 동일한 부위에 발라 귀의 염증을 유도하였다. 1시간 후, 실험예 1의 방법과 같이 귀의 두께를 측정하여 염증을 저해하는 정도를 비교하였으며, 그 결과는 다음 표 2에 나타낸 바와 같다.Nonsteroidal compounds and cyclooxygenase inhibitors have high inhibitory activity against arachidonic acid-induced inflammation, and each of them is used in an appropriate amount to compare the anti-inflammatory activity between After dissolving in acetone, it was applied to the ears of male ICR rats (18-22g), and after 30 minutes, 2% arachidonic acid was applied to the same site to induce ear inflammation. After 1 hour, the degree of inhibition of inflammation was measured by measuring the thickness of the ears as in Experimental Example 1, and the results are shown in Table 2 below.

상기 실험예 1, 2의 결과인 표1과 표2에서 살펴볼 수 있는 바와같이 본 발명에서 제조된 다이아네마이신을 쥐의 귀에 0.03~2.0mg의 농도로 처리했을 때 크로톤 오일이나 아라키돈산에 의해 유도되는 귀의 염증에 대한 저해활성을 확인할 수 있었으며, 아라키돈산 보다 크로톤 오일에 의해 유도되는 귀의 염증에 대한 저해활성이 높음을 알 수 있다.As can be seen in Tables 1 and 2, which are the results of Experimental Examples 1 and 2, when treated with a concentration of 0.03 to 2.0 mg of the dainaecin prepared in the present invention, it was induced by croton oil or arachidonic acid. It was confirmed that the inhibitory activity against the inflammation of the ear, and the inhibitory activity against the inflammation of the ear induced by croton oil than the arachidonic acid is higher.

또한, 크로톤 오일에 의해 유도되는 귀의 염증에 대한 다이아네마이신의 IC은 0.8mg/ear로서 항염 활성이 비교적 높았으나, 시판되고 있는 항염제제인 프레드니솔론(IC=0.4mg/ear)의 항염 활성과 비교했을때 다이아네마이신의 항염 활성이 상대적으로 낮았다. 그러나 프레드니솔론과 같이 높은 항염 활성을 보여 항염제제로 개발된 스테로이드 화합물은 앞서 서술한 여러가지 문제점 외에도 항균활성이 전혀 없어 항염증 피부연고제의 성분으로 스테로이드 화합물 외에도 항세균, 항진균 항생물질을 첨가해야 하는 문제점을 고려해 볼 때, 미생물에서 유래된 천연물로서 그람 양성, 그람 음성 세균에 항균활성을 가지고 있고 LD이 10mg 이상/ear으로서 비교적 안전하게 사용할 수 있는 본 발명의 다이아네마이신의 피부작용 항염제로의 사용 가능성이 매우 높다.In addition, IC of 0.84 / ear was relatively high in anti-inflammatory activity against ear inflammation induced by croton oil, but compared with anti-inflammatory activity of commercially available anti-inflammatory agent, prednisolone (IC = 0.4 mg / ear). At the same time, the anti-inflammatory activity of dianamine is relatively low. However, the steroid compound developed as an anti-inflammatory drug with high anti-inflammatory activity, such as prednisolone, has no antimicrobial activity in addition to the various problems described above. As a natural product derived from microorganisms, there is a high possibility of use of the diainemycin of the present invention as a skin action anti-inflammatory agent which has antimicrobial activity against Gram-positive and Gram-negative bacteria and which LD can be used relatively safely as 10 mg / ear or more. .

Claims (2)

방선균으로부터 분리된 다이아네마이신을 유효성분으로 함유하는 항염증작용제.An anti-inflammatory agent containing dianemycin isolated from actinomycetes as an active ingredient. 제1항에 있어서, 상기 방선균은 스트렙토마이세스속(Streptomyces sp.) MT 2705-4(KCTC 8651P)임을 특징으로 하는 항염증작용제.The anti-inflammatory agent according to claim 1, wherein the actinomycetes is Streptomyces sp. MT 2705-4 (KCTC 8651P).
KR1019950011228A 1995-05-09 1995-05-09 Anti-inflammatory agent containing streptomyces s.p mt2705-4 as activating component KR0149810B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950011228A KR0149810B1 (en) 1995-05-09 1995-05-09 Anti-inflammatory agent containing streptomyces s.p mt2705-4 as activating component

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950011228A KR0149810B1 (en) 1995-05-09 1995-05-09 Anti-inflammatory agent containing streptomyces s.p mt2705-4 as activating component

Publications (2)

Publication Number Publication Date
KR960040362A KR960040362A (en) 1996-12-17
KR0149810B1 true KR0149810B1 (en) 1998-10-15

Family

ID=19413932

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950011228A KR0149810B1 (en) 1995-05-09 1995-05-09 Anti-inflammatory agent containing streptomyces s.p mt2705-4 as activating component

Country Status (1)

Country Link
KR (1) KR0149810B1 (en)

Also Published As

Publication number Publication date
KR960040362A (en) 1996-12-17

Similar Documents

Publication Publication Date Title
CA1046439A (en) Physiologically active substances from penicillium citrinum
DE3006215C2 (en)
Lee et al. Cyclic peptides of the nocardamine class from a marine-derived bacterium of the genus Streptomyces
JPH05292948A (en) New large ring lactone and microorganism capable of producing the same
KR100366258B1 (en) Novel substances kf-1040 and process for producing the same
KR100729437B1 (en) The extracts of corylopsis coreana and tellimagrandin i isolated from same having antifungal activity
KR0149810B1 (en) Anti-inflammatory agent containing streptomyces s.p mt2705-4 as activating component
FR2568892A1 (en) NOVEL SANDRAMYCIN ANTIBIOTIC, PROCESS FOR PREPARING THE SAME, BIOLOGICALLY PURE CULTURE OF MICROORGANISM NOCARDIOIDES SP, ATCC NO 39419, AND PHARMACEUTICAL COMPOSITION CONTAINING SANDRAMYCIN
RU2134694C1 (en) Aminooligosaccharide "sk-4416", method of its synthesis, inhibitor of saccharide hydrolase and antibacterial agent
US4376778A (en) Antibiotic substances and processes for production thereof
Kiran et al. Biotransformation of α-cedrol and caryophyllene oxide by the fungus Neurospora crassa
JPH03141290A (en) Antitumor antibiotic bmy-41339
JP3786461B2 (en) New physiologically active substance
KR100322876B1 (en) Composition for the treatment of Helicobacter pylori origin stomach ulcer and duodenal ulcer
EP0037736B1 (en) Mycoplanecin derivatives, their preparation and pharmaceutical compositions containing them
US5096884A (en) Glidobactin pf-1 peptide antibiotics
JPS6024717B2 (en) antibiotic mycoplanesin
CA2145204A1 (en) Antibiotic agents
KR100543977B1 (en) Extracts of Chloranthus japonicus having chitin synthase ? inhibitory activity and a novel compound isolated from same
FR2464265A1 (en) NOVEL DIHYDRO-3,4-HYDROXY-4 (HYDROXY-3-PYRIDYL-2) -5-METHYL-4H-PYRROLECARBOXAMIDE-2 ANTIBIOTIC SUBSTANCE, USEFUL AS A MEDICAMENT AND PROCESS FOR PREPARING THE SAME USING A NEW MICROORGANISM STRAIN
KR100250834B1 (en) Streptomyces sp., nerve cell protecting compound derived from streptomyces sp. and process for preparing thereof
JP2002020387A (en) Antibiotic substance in xanthobaccin group
JP2827417B2 (en) Demethyl allosamidine and its production
CH646982A5 (en) TALLYSOMYCIN DERIVATIVES, THEIR PRODUCTION PROCESS AND MEDICAMENTS CONTAINING THEM.
KR100273743B1 (en) Macrolactin f, extract preparation from culture medium of streptomyces sp. yb-401, having depression effect of cholesterol biosynthesis

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030512

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee